Functional Parameters of Physiological Systems of Laboratory Primates after Administration of Doxorubicin and Transplantation of Mesenchymal Stem Cells
- Authors: Agrba V.Z.1, Agrba V.Z.1, Karal-ogly D.D.1, Kal’sina S.S.1, Konoplyannikov A.G.1, Gvozdik T.E.1, Gvaramiya I.A.1, Klots I.N.1, Mukhametzyanova E.I.1, Chuguev Y.P.1, Shamsutdinova O.A.1, Araviashvili D.E.1, Porkhanov V.A.1, Lapin B.A.1
-
Affiliations:
- Research Institute of Medical Primatology
- Issue: Vol 165, No 1 (2018)
- Pages: 115-120
- Section: Cell Technologies in Biology and Medicine
- URL: https://journals.rcsi.science/0007-4888/article/view/240039
- DOI: https://doi.org/10.1007/s10517-018-4111-0
- ID: 240039
Cite item
Abstract
We studied physiological parameters of rhesus monkeys after administration of anthracycline antibiotic doxorubicin. Intravenous administration of the drug caused intoxication manifested in in an abrupt body weight loss, baldness, vomiting, and exicosis. Intoxication in monkeys determined by the damaging effects of doxorubicin on organs and tissues is also characterized by significant changes in the blood: leukopenia, thrombocytopenia, neutropenia, monocytopenia, lymphocytosis, and a sharp drop of CD20+ B cell content. The total protein and albumin content in the blood significantly decreased. A sharp increase in C-reactive protein was also accompanied by an increase in activity of proinflammatory cytokine IL-6. Transplantation of mesenchymal stem cells in some cases can significantly alleviate doxorubicin-induced damage to organs and maintain normal clinical status of monkeys after two injections of the drug. Late transplantation of stem cells does not have a protective effect and does not protect the animals from the damaging effects of doxorubicin. We found that the protective effect of mesenchymal stem cells depends on the dose of the drug, total number of cells, and the time of their transplantation. It should be noted that human and monkey mesenchymal stem cells produce similar regenerative effects, at least in the doxorubicin toxicity model.
About the authors
V. Z. Agrba
Research Institute of Medical Primatology
Author for correspondence.
Email: agrba-vz@mail.ru
Russian Federation, Sochi
V. Z. Agrba
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
D. D. Karal-ogly
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
S. Sh. Kal’sina
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
A. G. Konoplyannikov
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
T. E. Gvozdik
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
I. A. Gvaramiya
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
I. N. Klots
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
E. I. Mukhametzyanova
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
Yu. P. Chuguev
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
O. A. Shamsutdinova
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
D. E. Araviashvili
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
V. A. Porkhanov
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi
B. A. Lapin
Research Institute of Medical Primatology
Email: agrba-vz@mail.ru
Russian Federation, Sochi